Tadalafil analgesia in experimental arthritis involves suppression of intra‐articular TNF release
Authors:
Open Access
- 9 May 2011
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 164 (2b) , 828-835
Abstract
BACKGROUND AND PURPOSE We investigated the effect of the phosphodiesterase‐5 inhibitor, tadalafil, on the acute hypernociception in rat models of arthritis.EXPERIMENTAL APPROACH Rats were treated with either an intra‐articular injection of zymosan (1 mg) or surgical transection of the anterior cruciate ligament (as an osteoarthritis model). Controls received saline intra‐articular or sham operation respectively. Joint pain was evaluated using the articular incapacitation test measured over 6 h following zymosan or between 4 and 7 days after anterior cruciate ligament transection. Cell counts, tumour necrosis factor‐α (TNF‐α), interleukin‐1 (IL‐1), and the chemokine, cytokine‐induced neutrophil chemoattractant‐1 (CINC‐1) were measured in joint exudates 6 h after zymosan. Groups received tadalafil (0.02–0.5 mg·kg−1per os) or saline 2 h after intra‐articular zymosan. Other groups received the µ‐opioid receptor antagonist naloxone or the cGMP inhibitor 1H‐[1,2,4] oxadiazolo [4,3‐a] quinoxalin‐1‐one (ODQ) before tadalafil.KEY RESULTS Tadalafil dose‐dependently inhibited hypernociception in zymosan and osteoarthritis models. In zymosan‐induced arthritis, tadalafil significantly decreased cell influx and TNF‐α release but did not alter IL‐1 or CINC‐1 levels. Pretreatment with ODQ but not with naloxone prevented the anti‐inflammatory effects of tadalafil.CONCLUSIONS AND IMPLICATIONS Therapeutic oral administration of tadalafil provided analgesia mediated by guanylyl cyclase and was independent of the release of endogenous opioids. This effect of tadalafil was associated with a decrease in neutrophil influx and TNF‐α release in inflamed joints.Keywords
This publication has 27 references indexed in Scilit:
- Cilomilast for COPDChest, 2006
- Differential Effects of Phosphodiesterase-5 Inhibitors on Hypoxic Pulmonary Vasoconstriction and Pulmonary Artery Cytokine ExpressionThe Annals of Thoracic Surgery, 2006
- Phosphodiesterase inhibitorsBritish Journal of Pharmacology, 2006
- Tumour necrosis factor-α mediates neutrophil migration to the knee synovial cavity during immune inflammationEuropean Journal of Pharmacology, 2004
- Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP StimulationMolecular Pharmacology, 2004
- Periarthritis promotes gait disturbance in zymosan-induced arthritis in ratsInflammation Research, 1999
- Identification and Function of Cyclic Nucleotide Phosphodiesterase Isoenzymes in Airway Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- Cyclic GMP and cGMP-binding Phosphodiesterase Are Required for Interleukin-1-induced Nitric Oxide Synthesis in Human Articular ChondrocytesJournal of Biological Chemistry, 1998
- Cyclic nucleotide phosphodiesterases: functional implications of multiple isoformsPhysiological Reviews, 1995
- The pivotal role of tumour necrosis factor α in the development of inflammatory hyperalgesiaBritish Journal of Pharmacology, 1992